Patients Association report that finds patients with common conditions such as rheumatoid arthritis, psoriasis and ulcerative colitis are being switched to new medicines without receiving the support they need to understand any changes, or to monitor and manage side effects
Report from the Royal College of General Practitioners giving an overview of the current legal situation regarding medicinal cannabis, the different forms it is available in, the conditions for which there is some, if limited, clinical evidence of benefit, and
The voluntary scheme for branded medicines pricing and access is a non-contractual voluntary agreement between the Department of Health and Social Care (DHSC) and the Association of the British Pharmaceutical Industry (ABPI). DHSC is acting on behalf of the UK government,
A training module developed for NHS 111 health advisors and pharmacy teams to help describe the NHS Urgent Medicine Supply Advanced Service (NUMSAS) and to illustrate the change in the patient journey since its introduction.
Fifth annual report of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR), which was established in 2013 to support Public Health England (PHE) in the delivery of the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. It
Report that looks at how to best harness advances in science to bring innovative drugs to patients. It is designed to help us reshape the landscape for drug discovery and development – and create tomorrow’s cancer treatments.
This guidance document provide information on the 2018/19 Community Pharmacy Contractual Framework National Audit, which is focused on the provision of seasonal influenza vaccination to people with diabetes.
This guidance document sets out the requirements in order to participate in the Community Pharmacy Quality Payments Scheme. The Scheme will reward community pharmacies for delivering quality criteria in all three of the quality dimensions: Clinical Effectiveness, Patient Safety and
Research into patents and connected patent families using keywords relevant to point-of-care (POC) diagnostic tests for addressing antimicrobial resistance. This research analysed what patents are being filed and therefore what technology is being developed. The report assesses the implications on
This further letter has been issued which provides additional guidance to clinicians and organisations following the rescheduling of cannabis-based products for medicinal use. This clarifies the status of the clinical guidance issued, and provides further clarification in relation to synthetic
Following the Government’s announcement to reschedule certain cannabis-based products for medicinal use, NHS England has provided guidance to clinicians following the re-scheduling which sets out our expectations of what this regulatory change will mean in practice for clinicians working in
Brief that aims to inform discussions about stimulating more meaningful productivity in terms of pharmaceutical R&D. More specifically, it explores how R&D efforts can be steered to areas of unmet clinical needs and how efficiency in the R&D process can
The national dose banding tables are to be used by hospital trust pharmacy teams to ensure a standard approach to dose banding of chemotherapy across all hospital trusts.
This guidance on the dispensing of adrenaline auto-injectors (150microgram) has been developed for pharmacies and dispensing GP practices. This validation protocol has been developed to ensure consistent practice nationally and to prevent the need for any local re-interpretation.
House of Commons Health and Social Care Committee report that identifies that tackling antimicrobial resistance needs to be firmly established as a ‘top five policy priority’ for the government in order to help prevent the virtual loss of worldwide modern
This Q&A has been developed for pharmacies and dispensing GP practices about the EpiPen and EpiPen Junior Supply issue.
Experts in children’s allergies have developed the advice in this letter to support parents and guardians of children who use Epipen Junior 150mcg.
Evidence-based recommendations on burosumab (Crysvita) for X‑linked hypophosphataemia in children and young people. Burosumab is recommended, within its marketing authorisation, for treating X‑linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults. Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs. It recommends: Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as